Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Acts as a transcriptional coactivator of serum response factor (SRF). Additionally we are shipping MKL2 Kits (4) and MKL2 Proteins (3) and many more products for this protein.
Showing 10 out of 35 products:
Taken together, these findings suggest that MKL1 (show MKL1 Antibodies) and MKL2 are present at synapses and involved in dendritic spine maturation.
Study showed that MRTF-A (show MKL1 Antibodies) and MRTF-B were upregulated in pancreatic cancer tissues supporting the hypothesis that both of them are oncogenes in pancreatic cancer.
While disruption of the MKL2:SRF axis has been associated with severe microcephaly and disordered brain development in multiple model systems, the role of this transcription factor complex has not been previously demonstrated in human brain development.
There were multiple independent HIV integrations in several genes, including MKL2 and BACH2 (show BACH2 Antibodies); many of these integrations were in clonally expanded cells.
MKL1 (show MKL1 Antibodies)/2 depletion resulted in Ras activation, elevated p16 expression and hypophosphorylation of the retinoblastoma (Rb) protein in DLC1 (show DYNLL1 Antibodies)-deficient hepatocellular carcinoma cells.
Based on a recurrent translocation t(11;16)(q13;p13), the C11orf95-MKL2 fusion gene has been found in eight further cases of chondroid lipomas.
study provides evidence that MKL1 (show MKL1 Antibodies)/2 mediates cancerous transformation in DLC1 (show DYNLL1 Antibodies)-deficient hepatocellular and mammary carcinoma cells
C11orf95-MKL2 is the resulting fusion oncogene (show RAB1A Antibodies) of t(11;16)(q13;p13) in chondroid lipoma.
dominant negative MKL2 blocked differentiation-induced expression of SRF target genes skeletal alpha-actin and alpha-myosin heavy chain and blocked differentiation of the myoblasts to myotubes in vitro.
BMP signaling modulates VSMC phenotype via cross-talk with the RhoA/MRTFs pathway, and may contribute to the development of the pathological characteristics observed in patients with PAH and other obliterative vascular diseases.
BRG1 promotes transcription of endothelial Mrtfa and Mrtfb, which elevates expression of SRF and SRF target genes that establish embryonic capillary integrity.
MRTF-A (show MKL1 Antibodies)/B depletion results in an increase in the cell surface expression of ICAM-1 (show ICAM1 Antibodies) and interactions between HAoECs and leukocytes
Either MRTF-A (show MKL1 Antibodies) or MRTF-B is dispensable for cardiac development, whereas deletion of both causes a spectrum of abnormalities ranging from reduced cardiac contractility and adult onset heart failure to neonatal lethality accompanied by sarcomere disarray.
These results identify SRF and its MRTF cofactors as major transcriptional regulators of endothelial cell junctional stability, guaranteeing physiological functions of the cerebral microvasculature.
Suggest role for nuclear RhoA (show RHOA Antibodies) signaling in MRTF-dependent gene expression in smooth muscle cells.
Myocardin (show MYOCD Antibodies)-related transcription factor (MRTF)-A (show MKL1 Antibodies) and MRTF-B (MKL1 (show MKL1 Antibodies) and MKL2, respectively) are enriched in the perinuclear space of epicardial cells during development.
MKL1/2 and ELK4 co-regulate distinct serum response factor (SRF) transcription programs in macrophages.
Smad2 (show SMAD2 Antibodies) interaction with MRTFB seems to be a novel and important mechanism underlying neural crest cell differentiation to vascular smooth muscle cells.
MRTF-B knockdown leads to increase in S and G2/M populations and downregulation of cyclin (show PCNA Antibodies)-CDK (show CDK4 Antibodies) inhibitors p27Kip1 (show CDKN1B Antibodies), p18Ink4c (show CDKN2C Antibodies) and 19Ink4d as well as upregulation of p21Waf1 and cyclin D1 (show CCND1 Antibodies).
Data suggest that MKL1 (show MKL1 Antibodies) and MKL2 are expressed in megakaryocytes and platelets; megakaryocytes lacking expression of MKL1 (show MKL1 Antibodies) and/or MKL2 have both defective megakaryocytopoiesis and thrombopoiesis.
Acts as a transcriptional coactivator of serum response factor (SRF). Required for skeletal myogenic differentiation.
MKL/myocardin-like protein 2
, megakaryoblastic leukemia 2
, myocardin-related transcription factor B
, MKL/myocardin-like 2
, megakaryoblastic leukemia 2 protein
, gene trap insertion site 4-1